Q4 2024 Ligand Pharmaceuticals Inc Earnings Call Transcript

Feb 27, 2025 / 01:30 PM GMT

Release Date Price: €114 (+0.88%)

Transcript 10-K8-K

Key Points

Positve

Ligand Pharmaceuticals Inc (LGND) reported a 28% increase in royalty revenue and a 40% increase in core adjusted EPS for 2024.
The company has a strong financial position with over $250 million in cash and investments and no debt.
Ligand Pharmaceuticals Inc (LGND) successfully launched two new commercial products, Veronaarma Auteuve and Merck's capaci, both exceeding sales expectations.
The company has a diversified portfolio of commercial stage royalty assets and a robust pipeline of development stage opportunities.
Ligand Pharmaceuticals Inc (LGND) has restructured its business model to focus on profitable and compounding growth, reducing cash operating expenses by over 50%.

Negative

GAAP net loss for 2024 was $4 million, a decline from the previous year's GAAP net income of $53.8 million.
Total R&D and G&A operating expenses increased by 29% in 2024 due to higher non-cash stock-based compensation expenses.
The company experienced a decline in GAAP net income due to non-cash items including a financial royalty asset impairment.
Ligand Pharmaceuticals Inc (LGND) faces risks and uncertainties related to forward-looking statements and market conditions.
The company has a significant reliance on the success of its royalty-generating programs and new product launches for future growth.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LGND.OQ - Ligand Pharmaceuticals Inc
Q4 2024 Ligand Pharmaceuticals Inc Earnings Call
Feb 27, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning everyone and welcome to yan's 4th quarter and full year 2024 earnings call. During the call today, we will review the financial results we released earlier today and provide commentary on our partner pipeline and business development activity, followed by a question and answer session.

Our earnings release and a link to today's webcast can be found in the investor relations section of our website at lichen.com.

With me on the call today are CEO Todd Davis, Paul Hadden, senior Vice President of Investments and Business Development, Chief Financial Officer Thabo Espinoza, and Vice President of Strategic Planning and Investment Analytics, Lauren Hay.

This call is being recorded and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.